171 related articles for article (PubMed ID: 30340752)
1. [Hot topics about early clinical trials at ASCO congress 2018: News pathways, new targets, new associations].
Auvray M; Baylot C; Blanc-Durand F; Borcoman E; Pons-Tostivint E; Vignot S
Bull Cancer; 2018 Nov; 105(11):1084-1093. PubMed ID: 30340752
[TBL] [Abstract][Full Text] [Related]
2. Emerging new anticancer therapies in 2013.
Gomez-Roca C; Delord JP
Curr Opin Oncol; 2014 May; 26(3):357-62. PubMed ID: 24709976
[TBL] [Abstract][Full Text] [Related]
3. [ESMO ECCO 2015: The highlights of immunotherapy and targeted therapies].
Bonnet C; Beinse G; Cabel L; Cochereau D; Lavaud P; Rochefort P; Tabouret E; Turpin A; Verlingue L; Vicier C; Massard C
Bull Cancer; 2016 Jun; 103(6):594-603. PubMed ID: 27229364
[TBL] [Abstract][Full Text] [Related]
4. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.
Masters GA; Krilov L; Bailey HH; Brose MS; Burstein H; Diller LR; Dizon DS; Fine HA; Kalemkerian GP; Moasser M; Neuss MN; O'Day SJ; Odenike O; Ryan CJ; Schilsky RL; Schwartz GK; Venook AP; Wong SL; Patel JD
J Clin Oncol; 2015 Mar; 33(7):786-809. PubMed ID: 25605863
[No Abstract] [Full Text] [Related]
5. [American Society of Clinical Oncology (ASCO) 2011 essential data: the editorial board of the Bulletin du Cancer point of view].
Vignot S; Bay JO; Blay JY; Gonçalves A; Massard C; Thariat J; Wislez M; André T
Bull Cancer; 2011 Dec; 98(12):1509-23. PubMed ID: 22182714
[TBL] [Abstract][Full Text] [Related]
6. [Current status of therapeutic approaches with targeted therapies in malignant thyroid cancer. Highlights from the 2011 ASCO Congress].
Uecker FC; Laban S; Knecht R
HNO; 2012 May; 60(5):398, 400-3. PubMed ID: 22570003
[TBL] [Abstract][Full Text] [Related]
7. American Society of Clinical Oncology 41st annual meeting.
Dillman RO
Expert Opin Biol Ther; 2005 Aug; 5(8):1117-27. PubMed ID: 16050788
[TBL] [Abstract][Full Text] [Related]
8. Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016.
Gulley JL; Repasky EA; Wood LS; Butterfield LH
J Immunother Cancer; 2017 Jul; 5(1):55. PubMed ID: 28716068
[TBL] [Abstract][Full Text] [Related]
9. Consistency of phase III clinical trial abstracts presented at an annual meeting of the American Society of Clinical Oncology compared with their subsequent full-text publications.
Tam VC; Hotte SJ
J Clin Oncol; 2008 May; 26(13):2205-11. PubMed ID: 18445846
[TBL] [Abstract][Full Text] [Related]
10. "Tumor immunology meets oncology" (TIMO) X, May 23-24, 2014, Halle/Saale, Germany.
Quandt D; Seliger B
Cancer Immunol Immunother; 2015 Apr; 64(4):519-26. PubMed ID: 25680628
[TBL] [Abstract][Full Text] [Related]
11. [Immune checkpoints inhibitors: Recent data from ASCO's meeting 2017 and perspectives].
Kfoury M; Disdero V; Vicier C; Le Saux O; Gougis P; Sajous C; Vignot S
Bull Cancer; 2018; 105(7-8):686-695. PubMed ID: 29933886
[TBL] [Abstract][Full Text] [Related]
12. Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.
Mandal R; Chan TA
Cancer Discov; 2016 Jul; 6(7):703-13. PubMed ID: 27107038
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
14. Cancer Nanomedicine: Lessons for Immuno-Oncology.
Sengupta S
Trends Cancer; 2017 Aug; 3(8):551-560. PubMed ID: 28780932
[TBL] [Abstract][Full Text] [Related]
15. Summary of presentations from the 46th annual meeting of the American Society Of Clinical Oncology (2010): focus on developmental therapeutics related to lung cancer.
Morgensztern D; Pennell NA; Subramanian J; Govindan R
Clin Lung Cancer; 2011 Mar; 12(2):94-9. PubMed ID: 21550555
[TBL] [Abstract][Full Text] [Related]
16. American Society of Clinical Oncology Developing First Clinical Trial.
Brower V
J Natl Cancer Inst; 2015 Nov; 107(11):djv356. PubMed ID: 26538625
[No Abstract] [Full Text] [Related]
17. [The breakthrough of personalized medicine, new hopes and new challenges].
Flippot R; Massard C; Auclin E; Azria D; Bourien H; Rochigneux P; Schernberg A; Verlingue L; Zafrani L; Vignot S
Bull Cancer; 2017 Sep; 104(9):735-743. PubMed ID: 28807365
[TBL] [Abstract][Full Text] [Related]
18. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
[TBL] [Abstract][Full Text] [Related]
19. Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors.
Aspeslagh S; Marabelle A; Soria JC; Armand JP
Chin Clin Oncol; 2015 Dec; 4(4):48. PubMed ID: 26730760
[TBL] [Abstract][Full Text] [Related]
20. New horizons for platinum-resistant ovarian cancer: insights from the 2023 American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) Annual Meetings.
El Bairi K; Madariaga A; Trapani D; Al Jarroudi O; Afqir S
Int J Gynecol Cancer; 2024 May; 34(5):760-772. PubMed ID: 38101815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
